Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

Digestive and Liver Disease

Volumn 40, Issue 9, 2008, Pages 737-742

  Tursi, A ^a   Brandimarte, G ^b   Elisei, W ^b   Giorgetti, G M ^c   Inchingolo, C D ^a   Aiello, F ^d  

^a Lorenzo Bonomo Hospital   (Italy)

^b Cristo Re Hospital   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cell proliferation; Colonic mucosa; Diverticular disease; Mesalazine; Treatment

Indexed keywords

KI 67 ANTIGEN; MESALAZINE; PENTACOL; RIFAXIMIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLON DIVERTICULOSIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTESTINE CELL; INTESTINE CRYPT; LONG TERM CARE; MALE; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CELL PROLIFERATION; COLONOSCOPY; DIVERTICULOSIS, COLONIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; KI-67 ANTIGEN; MALE; MESALAMINE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 48149115049     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.02.022     Document Type: Article

References (33)

1. Floch M.H., and Bina I. The natural history of diverticulitis: fact and theory. J Clin Gastroenterol 38 Suppl. 5 (2004) 2-7
2. Capocaccia R., Colonna M., Corazziari E., De Angelis R., Francisci S., Micheli A., et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 13 (2002) 831-839
3. McCallum A., Eastwood M.A., Smith A.N., and Fulton P.M. Colonic diverticulosis in patients with colorectal cancer and in controls. Scand J Gastroenterol 23 (1988) 284-286
4. Morini S., de Angelis P., Manurita L., and Colavolpe V. Association of colonic diverticula with adenomas and carcinomas. A colonoscopic experience. Dis Colon Rectum 31 (1988) 793-796
5. Kieff B.J., Eckert G.J., and Imperiale T.F. Is diverticulosis associated with colorectal neoplasia? A cross-sectional colonoscopic study. Am J Gastroenterol 99 (2004) 2007-2011
6. Stefansson A., Ekbom A., Sparen P., and Pählman L. Association between sigmoid diverticulitis and left-sided colon cancer: a nested, population-based, case control study. Scand J Gastroenterol 39 (2004) 743-747
7. Morini S., Hassan C., Zullo A., De Francesco, Festa V., Barberani F., et al. Diverticular disease as a risk factor for sigmoid adenomas. Digest Liver Dis 34 (2002) 635-639
8. Citarda F., Tomaselli G., Capocaccia R., Barcherini S., Crespi M., and Italian Multicentre Study Group. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 48 (2001) 812-815
9. Fearon E.R., and Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 61 (1990) 759-767
10. Risio M., Coverlizza S., Ferrari A., Candelaresi G.L., and Rossini F.P. Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas and adenocarcinomas of the large bowel. Gastroenterology 94 (1988) 899-906
11. Lipkin M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res 48 (1988) 235-245
12. Anti M., Armuzzi A., Morini S., Iascone E., Pignataro G., Coco C., et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 48 (2001) 238-246
13. Morini S., Hassan C., Zullo A., De Francesco V., Burattini O., Margiotta M., et al. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. Aliment Pharmacol Ther 21 (2005) 1385-1390
14. Tursi A., Brandimarte G., Elisei W., Inchingolo C.D., and Aiello F. Epithelial cell proliferation of the colonic mucosa in different degrees of colonic diverticular disease. J Clin Gastroenterol 40 (2006) 306-311
15. Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis 37 (2005) 381-388
16. Tursi A. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacother 8 (2007) 299-307
17. Tursi A. Acute diverticulitis of the colon-current medical therapeutic management. Expert Opin Pharmacother 5 (2004) 55-59
18. Tursi A. Mesalazine for diverticular disease of the colon-a new role for an old drug. Expert Opin Pharmacother 6 (2005) 69-74
19. Reinacher-Schick A., Schoeneck A., Graeven U., Schwarte-Waldhoff I., and Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 24 (2003) 443-451
20. Reinacher-Schick A., Seidensticker F., Petrasch S., Reiser M., Philippou S., Theegarten D., et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32 (2000) 245-254
21. Results of a Consensus Development Conference. Diagnosis and treatment of diverticular disease. Surg Endosc 1999;13:430-6.
22. Mills S.J., Mathers J.H., Chapman P.D., Burn J., and Gunn A. Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut 48 (1991) 41-46
23. Holt P.R., Moss S.F., Kapetamakis A.M., Petros A., and Wang S. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen?. Cancer Epidemiol Biomarkers Prev 6 (1997) 131-135
24. Noffsinger A.E., Miller M.A., Cusi M.V., and Fenoglio-Preiser C.M. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 78 (1996) 2307-2312
25. Herold C., Ocker M., Ganslmayer M., Gerauer H., Hahn E.G., and Schuppan D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 86 (2002) 443-448
26. Roncucci L., Scalmati A., and Ponz de Leon M. Pattern of cell kinetics in colorectal mucosa of patients with different types of adenomatous polyps of the large bowel. Cancer 68 (1991) 873-878
27. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Inchingolo CD, Danese S, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol, in press.
28. Langman M., and Boyle P. Chemoprevention of colorectal cancer. Gut 43 (1998) 578-585
29. Shiff S.J., Qioa L., Tsai L.L., and Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96 (1995) 491-503
30. Yang F., de Villiers W.J.S., McClain C.J., and Varilek G.W. Mesalamine modulates nuclear factor-κB/IκB-alpha in Caco-2 cells. Gastroenterology 112 Suppl. (1997) A1125
31. Kaiser G.C., Yan F., and Polk D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes. Gastroenterology 116 (1999) 602-609
32. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappaB. J Clin Invest 101 (1998) 1163-1174
33. Cheng Y., and Desreumaux P. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol 11 (2005) 309-314